November 10, 2022

BrightPath to Update the Pre-clinical Data of iPS-NKTat SITC 2022
Tokyo, Japan - November 10, 2022/ -- BrightPath Biotherapeutics (TSE Growth 4954), aclinical-stage biopharmaceutical company focused on developing novel cancer
immunotherapeutics, today announced a presentation of the pre-clinical data on iPS-NKT
program at the Society for Immunotherapy of Cancer Annual Meeting (SITC 2022,
November 8-12, Boston).
The presentation is available on the websites of BrightPath.
BrightPath’s abstract is as follows:
Title: A novel iPSC-derived CAR-invariant natural killer T (iNKT) cell therapy platform forhematologic malignancies and solid tumors(Abstract number: 290）
The presentation describes:• BrightPath produced the first-ever iPS-NKT Platform-derived prototype CAR-iPSNKTcells targeting CD19 or HER2 that demonstrated in vitro antitumor effects• CD19 CAR- or HER2 CAR-transduced iPSCs were differentiated into CAR-iNKT cells
in feeder cell-free culture conditions while maintaining CAR expression.
iPS-NKT is novel allogeneic cell therapy platform that uses natural killer T (NKT) cells
differentiated from iPSC for cancer treatment. At present, an investigator-initiated Phase 1 trialof iPS-NKT in patients with head and neck cancers is underway at Chiba University as theworld’s first clinical application of iPSC-derived NKT cells for cellular therapy.
iNKT cells are a rare subset of innate lymphocytes that bridge innate and adaptive immune
response. The most distinct feature of iNKT cells from other immune cells is the function toprime host endogenous T cells, which is expected to provide durability of response in theclinical practice.
One of the challenge is a clinical-scale manufacturing from such a rare subset and Use ofiPSC derived from iNKT cells is an ideal strategy to realize clinical scale production offunctional iNKT cells from such a rare population.
To demonstrate that CAR-transduced iPSC-derived iNKT cells provide a novel platform foreffective cancer immunotherapy, the killing activities of CD19 CAR- or HER2 CARtransduced iPSC-derived iNKT cells were investigated in this first set of studies.

About BrightPath:
BrightPath is a clinical stage biopharmaceutical company focused on the development of novel
cancer immuno-therapies to transform cancer treatment for refractory or progressive cancers
that cannot be treated with conventional standard therapies. BrightPath is actively involved indeveloping cell therapies currently in clinical trials, immunomodulatory antibodies and new drug
targeted at cancer specific neoantigens.
For more information, visit www.brightpathbio.com/english/index.html.
Forward-Looking Statements:
This news release contains forward-looking statements that are based on the current
expectations and beliefs of BrightPath. All statements, other than statements of historical fact,
are statements that could be deemed forward-looking statements. BrightPath cautions thatthese forward-looking statements do not guarantee our future financial results but involverisks and uncertainties that could cause actual results to differ materially from those
discussed in the forward-looking statements. These forward-looking statements speak only
as of the date of this press release and BrightPath assumes no duty to update forward-looking
statements, except as may be required by law.
Investor and Media Contact:+81-3-5840-7697
irpr@brightpathbio.com
www.brightpathbio.com/english/index.html